Brief report: a phase II "window-of-opportunity" frontline study of the MTOR inhibitor, temsirolimus given as a single agent in patients with advanced NSCLC, an NCCTG study.

Details

Language :

English

ISSN :

15560864

Volume :

7

Issue :

5

Database :

Complementary Index

Journal :

Journal of Thoracic Oncology

Publication Type :

Academic Journal

Accession number :

108126690

Full Text :

https://doi.org/10.1097/JTO.0b013e31824de0d6